Overview

• HSP-CAR30, developed by researchers at IR Sant Pau and partners, targets CD30 in refractory lymphomas, offering a new treatment option for patients with limited alternatives.
• In Phase I trials, the therapy achieved a 100% overall response rate, with 50% of patients reaching complete remission and 60% of those remaining relapse-free after 34 months.
• The therapy has advanced to Phase II, where preliminary data from 32 treated patients and 10 additional enrollees show over 55% achieving complete remission.
• HSP-CAR30 incorporates innovative strategies, including memory T cell expansion and cytokine support, to enhance durability and persistence of therapeutic effects.
• Safety remains a key strength, with no dose-limiting toxicities, only mild cytokine release syndrome in some cases, and no neurotoxicity reported.